Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results

[1]  P. Georg,et al.  PET/MRI in cervical cancer: Insights into tumor biology. , 2015 .

[2]  O. Catalano,et al.  Evaluation of Gynecologic Cancer with MR Imaging, 18F-FDG PET/CT, and PET/MR Imaging , 2015, The Journal of Nuclear Medicine.

[3]  Michael Forsting,et al.  Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging for Whole-Body Staging in Patients With Recurrent Gynecological Malignancies of the Pelvis: A Comparison to Whole-Body Magnetic Resonance Imaging Alone , 2014, Investigative radiology.

[4]  K. Sugimura,et al.  Fusion of PET and MRI for staging of uterine cervical cancer: comparison with contrast-enhanced (18)F-FDG PET/CT and pelvic MRI. , 2014, Clinical imaging.

[5]  Andrea Soricelli,et al.  Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues. , 2014, European journal of radiology.

[6]  Felix Nensa,et al.  Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  M. Miyazaki,et al.  Diffusion-weighted imaging reflects pathological therapeutic response and relapse in breast cancer , 2014, Breast Cancer.

[8]  M. Harisinghani,et al.  Apparent diffusion coefficient as a non-invasive predictor of treatment response and recurrence in locally advanced rectal cancer. , 2013, Clinical radiology.

[9]  M. Forsting,et al.  Correlation of the Apparent Diffusion Coefficient (ADC) with the Standardized Uptake Value (SUV) in Hybrid 18F-FDG PET/MRI in Non-Small Cell Lung Cancer (NSCLC) Lesions: Initial Results , 2013, Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.

[10]  Felix Nensa,et al.  Simultaneous 18F Choline Positron Emission Tomography/Magnetic Resonance Imaging of the Prostate: Initial Results , 2013, Investigative radiology.

[11]  D. Mitchell,et al.  The added role of MR imaging in treatment stratification of patients with gynecologic malignancies: what the radiologist needs to know. , 2013, Radiology.

[12]  Y. Huan,et al.  The value of apparent diffusion coefficient in the assessment of cervical cancer , 2013, European Radiology.

[13]  E. Sala,et al.  The revised FIGO staging system for uterine malignancies: implications for MR imaging. , 2012, Radiographics : a review publication of the Radiological Society of North America, Inc.

[14]  S. Jeong,et al.  18F-FDG Uptake by Metastatic Axillary Lymph Nodes on Pretreatment PET/CT as a Prognostic Factor for Recurrence in Patients with Invasive Ductal Breast Cancer , 2012, The Journal of Nuclear Medicine.

[15]  H. Cooper,et al.  Predicting Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Using 18FDG-PET/CT , 2012, Annals of Surgical Oncology.

[16]  A. Hongo,et al.  Measurement of SUVmax plus ADCmin of the primary tumour is a predictor of prognosis in patients with cervical cancer , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[18]  Dae Chul Jung,et al.  Additional value of MR/PET fusion compared with PET/CT in the detection of lymph node metastases in cervical cancer patients. , 2009, European journal of cancer.

[19]  P. Grigsby,et al.  Cervical cancer histology and tumor differentiation affect 18F‐fluorodeoxyglucose uptake , 2009, Cancer.

[20]  K. Sugimura,et al.  Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  E. Sala,et al.  [MRI of malignant neoplasms of the uterine corpus and cervix]. , 2007, Radiologia.

[22]  A. Levy.  MRI of Malignant Neoplasms of the Uterine Corpus and Cervix , 2008 .

[23]  P. Grigsby,et al.  The standardized uptake value for F‐18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival , 2007, Cancer.

[24]  P. Maisonneuve,et al.  Carcinoma of the cervix uteri , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[25]  P. Maisonneuve,et al.  Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[26]  G. Antoch,et al.  Lymph node staging with dual-modality PET/CT: enhancing the diagnostic accuracy in oncology. , 2006, European journal of radiology.

[27]  D. Matchar,et al.  FDG-PET for management of cervical and ovarian cancer. , 2005, Gynecologic oncology.

[28]  Thomas Beyer,et al.  Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Thomas Beyer,et al.  Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. , 2003, Radiology.

[30]  A. Kuten,et al.  Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  H. Hricak,et al.  Cervical Carcinoma: Computed Tomography and Magnetic Resonance Imaging for Preoperative Staging , 1995, Obstetrics and gynecology.

[32]  Y. Tanaka,et al.  Relationship between lymph node metastases and prognosis in patients irradiated postoperatively for carcinoma of the uterine cervix. , 1984, Acta radiologica. Oncology.

[33]  L. Lagasse,et al.  Results and complications of operative staging in cervical cancer: experience of the Gynecologic Oncology Group. , 1980, Gynecologic oncology.